Editas Medicine, Inc.
EDIT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | 0.02 | 0.13 |
| FCF Yield | -27.04% | -49.73% | -48.90% | -19.73% |
| EV / EBITDA | -2.53 | 0.16 | -0.19 | -3.70 |
| Quality | ||||
| ROIC | -33.09% | -37.39% | -16.70% | -24.18% |
| Gross Margin | 100.00% | 100.00% | 95.49% | -2,521.31% |
| Cash Conversion Ratio | 1.23 | 0.94 | 0.63 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.52% | 26.28% | 16.28% | 17.91% |
| Free Cash Flow Growth | -4.80% | 6.61% | 7.58% | 8.33% |
| Safety | ||||
| Net Debt / EBITDA | 1.23 | 1.49 | 2.19 | 0.95 |
| Interest Coverage | -25.52 | -34.37 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14.79 | -532.43 | -310.14 | -517.16 |